Assuming peripheral elimination: Its impact on the estimation of pharmacokinetic parameters of muscle relaxants

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 5, 1999, Pages 491-512

  Laurin, J ^a   Nekka, F ^a   Donati, F ^a   Varin, F ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Muscle relaxants; Peripheral concentrations; Peripheral elimination; Pharmacokinetic model; Pharmacokinetics; Volume of distribution

Indexed keywords

ATRACURIUM BESILATE; DOXACURIUM; MIVACURIUM; MUSCLE RELAXANT AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALGORITHMS; ATRACURIUM; COMPUTER SIMULATION; HALF-LIFE; HUMANS; ISOQUINOLINES; MIDDLE AGED; MODELS, BIOLOGICAL; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 0033363867     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. General treatment of mean residence time, clearance, and volume parameters in linear mamillary models with elimination from any compartment
2. General treatment of linear mamillary models with elimination from any compartment as used in pharmacokinetics
3. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination
4. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia
5. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients
6. Dose proportionality of cisatracurium
7. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium
8. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia
9. (Almost) Everything you learned about pharmacokinetics was (somewhat) wrong!
10. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
11. Pharmacokinetics and pharmacodynamics of a second dose of atracurium in anaesthetised patients
12. Pharmacokinetic-pharmacodynamic modeling of doxacurium: Effect of input rate
13. Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration
14. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure)
15. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia
16. Acethylcholinesterase and butyrylcholinesterase are expressed in the spinal meninges of monkeys and pigs
17. Determination of atracurium and laudanosine in human plasma by high-peformance liquid chromatography
18. Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium
19. High-performance liquid chromatographic assays with fluorometric detection for mivacurium isomers and their metabolites in human plasma
20. Volume of distribution as a function of time
21. Concept of a volume of distribution and possible errors in evaluation of this parameter
22. Relationship between drug concentration in plasma or serum and amount of drug in the body
23. Estimation of volume of distribution and half-life of a compound after rapid intravenous injection
24. Route of administration and drug metabolism
25. Effects of change in elimination on various parameters of the two-compartment open model
26. In vitro degradation of atracurium in human plasma
27. Pharmacokinetics of atracurium bezylate in healthy patients (after a single I.V. bolus dose)
28. A model for atracurium? [Editorial]
29. The in vitro degradation of cisatracurium, the R, cis-R-isomer of atracurium, in human and rat plasma
30. Importante of the organ-independent elimination of cisatracurium
31. Pharmacokinetics